SCHEMBL30944769

SCHEMBL30944769

CN(C(=O)c1cc2ccccc2[nH]1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.60
MAPT P10636 1/20 0.60
DAO P14920 1/20 0.60
HPGD P15428 1/20 0.60
SRD5A2 P31213 1/20 0.60
HSD17B10 Q99714 1/20 0.60
FLT3 P36888 1/20 0.57
LMNA P02545 2/20 0.51
IDO1 P14902 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HTR2C P28335 1/20 0.51
PDGFRB P09619 1/20 0.50
PDGFRA P16234 1/20 0.50
TP53 P04637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27254679 1.00 KDM4E (0.60) KDM4EMAPTDAOHPGDSRD5A2
SCHEMBL24896473 0.85 AR (0.49) KDM4EMAPTHPGDFLT3NPC1
SCHEMBL9410532 0.85 SMAD3 (0.59) FLT3PDGFRBPDGFRAPYGL
SCHEMBL27254461 0.84 PYGL (0.52) FLT3IDO1NPC1PYGL
SCHEMBL24896475 0.84 ATM (0.57) KDM4EMAPTHPGDHSD17B10FLT3
SCHEMBL4001756 0.84 KDM4E (0.55) KDM4EMAPTDAOHPGDSRD5A2
SCHEMBL378260 0.83 FLT3 (0.65) KDM4EMAPTDAOHPGDSRD5A2
SCHEMBL29595772 0.83 FLT3 (0.65) KDM4EMAPTDAOHPGDSRD5A2
SCHEMBL9410549 0.82 MEN1 (0.64) KDM4EMAPTHPGDFLT3LMNA
Hydrochloric Acid SCHEMBL35211567 0.82 FLT3 (0.62) KDM4EMAPTDAOHPGDSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638421-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR Eli Lilly and Company (US) 2025-10-29 EP disclosed
US-20250092041-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-03-20 US disclosed
WO-2024137426-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR ELI LILLY AND COMPANY (US) 2024-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092041-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR KDM4E 1278/4885MAPT 4437/4885DAO 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.